Open Orphan PLC - pharmaceutical services clinical research firm based in London - Says its subsidiary, hVIVO, will expand its Covid-19 characterisation study. Plans to add up to 20 more volunteers once regulatory approvals and clinical preparations are complete. Study produced for the UK government under hVIVO's supervision with Great Ormond Street Hospital for Children NHS Foundation Trust and virologists at Imperial College London. Initially, the study planned to inoculate up to 90 volunteers to enable identification of the most appropriate dose of the virus required to cause infection in a safe and controlled environment.
Says Poolbeg Pharma PLC raised GBP25 million in a placing of new shares at 10 pence per share, giving Poolbeg a market valuation of GBP50 million at IPO. Poolbeg is a clinical-stage infectious diseases company which was formed by Open Orphan to demerge certain development assets from its core services led business.
With finnCap as its nominated adviser and broker, Poolbeg is expected to start trading on London's AIM on Monday next week.
Breda office in the Netherlands wins EUR900,000 new contract with existing customer for clinical trial management. Completes acquisition of challenge agents manufacturer, CHIMagents Ltd.
Current stock price: 26.75p, up 5.9% on Wednesday afternoon
Year-to-date change: up 3.7%
By Scarlett Butler; scarlettbutler@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
